Microport Cardioflow Medtech

Microport Cardioflow Medtech FCF Margin

The Free Cash Flow Margin of Microport Cardioflow Medtech (2160.HK) as of Nov 6, 2026 is -74.69 %. In the previous year, Free Cash Flow Margin was -70.64 % — a change of 5.74% (lower).

FCF Margin

-74.69 %

YoY

5.74%

Last updated:

Free Cash Flow Margin of Microport Cardioflow Medtech is 2024 -74.69 % . Free Cash Flow Margin of Microport Cardioflow Medtech was 2023 -70.64 % . It decreases by 5.74% lower compared to the previous year.

The Microport Cardioflow Medtech FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2019
-890.32 CNY
Jan 1, 2020
-161.61 CNY
Jan 1, 2021
-134.43 CNY
Jan 1, 2022
-92.26 CNY
Jan 1, 2023
-70.64 CNY
Jan 1, 2024
-74.69 CNY
The Microport Cardioflow Medtech FCF Margin history
YEARFCF MarginYoY
-74.69 %+5.74%
-70.64 %-23.44%
-92.26 %-31.37%
-134.43 %-16.82%
-161.61 %-81.85%
-890.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Microport Cardioflow Medtech Stock analysis

What does Microport Cardioflow Medtech do? MicroPort CardioFlow Medtech Corp. develops and commercializes transcatheter and surgical solutions for valvular heart diseases, primarily focusing on the domestic market. The company's main products are the first-generation TAVI product VitaFlow and the second-generation TAVI product VitaFlow II, which are used for transcatheter aortic heart valve implantation. These products are sold to healthcare providers and hospitals within China, where the company operates under its holding company structure. The firm generates revenue through the sale of its medical devices, specifically the VitaFlow and VitaFlow II systems, targeting hospitals and medical institutions that require advanced cardiac solutions. As a domestic-focused entity, MicroPort CardioFlow's business model relies on the commercialization of its TAVI products within China's healthcare sector, with no mention of international markets or additional product lines beyond the two TAVI systems. Microport Cardioflow Medtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Microport Cardioflow Medtech stock

Free Cash Flow Margin of Microport Cardioflow Medtech is -74.69 % in 2024.

Free Cash Flow Margin of Microport Cardioflow Medtech changed from -70.64 % to -74.69 %, representing a 5.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Microport Cardioflow Medtech since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Microport Cardioflow Medtech with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Microport Cardioflow Medtech

All Key Metrics — Microport Cardioflow Medtech